BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 2021;41:747-95. [PMID: 34197702 DOI: 10.1002/cac2.12193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu ZN, Wang YK, Zhang L, Jia YN, Fei S, Ying XJ, Zhang Y, Li SX, Sun Y, Li ZY, Ji JF. Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy. World J Gastrointest Oncol 2021; 13(12): 2161-2179 [DOI: 10.4251/wjgo.v13.i12.2161] [Reference Citation Analysis]
2 Mei Y, Feng X, Feng T, Yan M, Zhu Z, Li T, Zhu Z. Adjuvant Chemotherapy in pT2N0M0 Gastric Cancer: Findings From a Retrospective Study. Front Pharmacol 2022;13:845261. [DOI: 10.3389/fphar.2022.845261] [Reference Citation Analysis]
3 Gao G, Li C, Fan W, Zhang M, Li X, Chen W, Li W, Liang R, Li Z, Zhu X. Brilliant glycans and glycosylation: Seq and ye shall find. Int J Biol Macromol 2021:S0141-8130(21)01713-X. [PMID: 34389387 DOI: 10.1016/j.ijbiomac.2021.08.054] [Reference Citation Analysis]
4 Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 2021;41:747-95. [PMID: 34197702 DOI: 10.1002/cac2.12193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, Jia Y, Miao R, Xue K, Li Z, Li Z, Ji J. Duration of Perioperative Chemotherapy in Locally Advanced Gastric Cancer: A "Less Is More" Question When ypN0 Is Achieved. Front Oncol 2021;11:775166. [PMID: 34926284 DOI: 10.3389/fonc.2021.775166] [Reference Citation Analysis]
6 Dan Zeng CD, Tong YX, Xiao AT, Gao C, Zhang S. Peripheral Lymphocyte Subsets Absolute Counts as Feasible Clinical Markers for Predicting Surgical Outcome in Gastric Cancer Patients After Laparoscopic D2 Gastrectomy: A Prospective Cohort Study. J Inflamm Res 2021;14:5633-46. [PMID: 34744447 DOI: 10.2147/JIR.S335847] [Reference Citation Analysis]
7 Wang W, Yang YJ, Zhang RH, Deng JY, Sun Z, Seeruttun SR, Wang ZN, Xu HM, Liang H, Zhou ZW. Standardizing the classification of gastric cancer patients with limited and adequate number of retrieved lymph nodes: an externally validated approach using real-world data. Mil Med Res 2022;9:15. [PMID: 35387671 DOI: 10.1186/s40779-022-00375-2] [Reference Citation Analysis]
8 Yang Y, Zheng J, Li Y. Comparison of 4 lymph node staging systems for the prognostic prediction of esophagogastric junction adenocarcinoma with ≤15 retrieved lymph nodes. Eur J Surg Oncol 2021:S0748-7983(21)00942-2. [PMID: 34876328 DOI: 10.1016/j.ejso.2021.11.133] [Reference Citation Analysis]
9 Wang J, Huang J, Wang H, Yang W, Bai Q, Yao Z, Li Q, Lv H, Chen B, Nie C, Xu W, Tu S, Li H, Chen X, Yang D. Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/1987705] [Reference Citation Analysis]
10 Liu Y, Zhai E, Chen J, Qian Y, Zhao R, Ma Y, Liu J, Huang Z, Cai S, Chen J. m6 A-mediated regulation of PBX1-GCH1 axis promotes gastric cancer proliferation and metastasis by elevating tetrahydrobiopterin levels. Cancer Commun (Lond) 2022. [PMID: 35261206 DOI: 10.1002/cac2.12281] [Reference Citation Analysis]
11 Xu SZ, Cai JC. Laparoscopic-Assisted Natural Orifice Specimen Extraction Gastrectomy Using an Auxiliary Incision-free Tube for Gastric Cancer. J Surg Res 2021;270:31-8. [PMID: 34628161 DOI: 10.1016/j.jss.2021.08.026] [Reference Citation Analysis]
12 Feng X, Chen X, Ye Z, Xiong W, Yao X, Wang W, Wang J, Chen L, Li Y. Laparoscopic Versus Open Total Gastrectomy for Advanced Gastric Cancer: A Multicenter, Propensity Score-Matched Cohort Study in China. Front Oncol 2021;11:780398. [PMID: 34966682 DOI: 10.3389/fonc.2021.780398] [Reference Citation Analysis]
13 Mei Y, Wang S, Feng T, Yan M, Yuan F, Zhu Z, Li T, Zhu Z. Nomograms Involving HER2 for Predicting Lymph Node Metastasis in Early Gastric Cancer. Front Cell Dev Biol 2021;9:781824. [PMID: 35004681 DOI: 10.3389/fcell.2021.781824] [Reference Citation Analysis]
14 Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 2021;22:1081-92. [PMID: 34252374 DOI: 10.1016/S1470-2045(21)00297-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2021;6:1015-24. [PMID: 34626550 DOI: 10.1016/S2468-1253(21)00313-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zhu XD, Huang MZ, Wang YS, Feng WJ, Chen ZY, He YF, Zhang XW, Liu X, Wang CC, Zhang W, Ying JE, Wu J, Yang L, Qin YR, Luo JF, Zhao XY, Li WH, Zhang Z, Qiu LX, Geng QR, Zou JL, Zhang JY, Zheng H, Song XF, Wu SS, Zhang CY, Gong Z, Liu QQ, Wang XF, Xu Q, Wang Q, Ji JM, Zhao J, Guo WJ. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX). Cancer Commun (Lond) 2022. [PMID: 35212487 DOI: 10.1002/cac2.12278] [Reference Citation Analysis]
17 Chen Y, He J, Liu D, Xiao J, Chen X, Tang H, Luo D, Shang C, Lian L, Peng J. Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis. BMC Cancer 2021;21:1328. [PMID: 34903191 DOI: 10.1186/s12885-021-09093-9] [Reference Citation Analysis]